{
  "title": "What this review means",
  "includeSubclaimIllustrations": false,
  "redteamReviewed": true,
  "accessNotice": "Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.",
  "overview": "Regulated GLP-1 medicines have causal clinical evidence; equivalent efficacy of unregulated research-chemical products has not been established.",
  "implications": "Overall Α applies to SC3, the preregistered clinical-equivalence proposition. It does not deny the efficacy of regulated GLP-1 medicines or prove that every research-market preparation is inactive. Product identity, exposure and clinical equivalence cannot be supplied by a chemical label or transferred from a registrational trial.",
  "limitations": "51 primary reports with 1 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation."
}